Goldman Sachs
BKYI

Goldman Sachs’s BIO-key International BKYI Stock Holding History

Goldman Sachs’s Portfolio BKYI Stock Details BKYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-67
Closed -$46K – 6235
2021
Q2 		$46K Buy
+67
New +$44K ﹤0.01% 6078
2021
Q1 		– Sell
-117
Closed -$74K – 6082
2020
Q4 		$74K Buy
+117
New +$74.1K ﹤0.01% 5334
2017
Q4 		– Sell
-12
Closed -$48K – 6349
2017
Q3 		$48K Buy
+12
New +$55.1K ﹤0.01% 6259

Other funds holding BKYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
MML Investors Services
MML Investors Services Springfield, Massachusetts $49B AUM 25.55% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

Goldman Sachs's BKYI Position: Q3 2021 in Review

Goldman Sachs sold out of BIO-key International (BKYI) in Q3 2021, closing a stake of 67 shares — an estimated $46K sold.

Goldman Sachs first reported a position in BKYI in Q3 2017 and held it in 3 quarters. The position peaked at $74K in Q4 2020. 12 funds tracked by Wall St. Rank hold BKYI as of Q3 2021.

  • Goldman Sachs reported no remaining BIO-key International position as of Q3 2021 after selling out during the quarter.
  • Goldman Sachs sold 67 BIO-key International shares in Q3 2021, an estimated $46K.
  • Goldman Sachs first reported a position in BIO-key International in Q3 2017 and held it in 3 quarters.
  • Goldman Sachs's BIO-key International position peaked at $74K in Q4 2020.
  • 12 funds tracked by Wall St. Rank held BIO-key International as of Q3 2021.

Based on Goldman Sachs's 13F filing for Q3 2021, filed 10 Nov 2021.